Leaving Flatland Behind – A View from Experience in 3D Adherent Cell Culture for Advanced Therapies June 18, 2024 Biomanufacturing, Bioprocessing
Double, Double, Experts Huddle, Cells & Bioprocess Bubble February 07, 2024 Bioprocessing, Exosomes / Extracellular Vesicles
From Elephant Ears to Ambr® Waves: A New Path Toward Scale & Abundance for Biomanufactured hMSCs… October 03, 2022 Biomanufacturing, Exosomes / Extracellular Vesicles, MSCs & Characterization
Versatile Manufacturing Formats for Your Adherent Cell Therapy “Triathlon” & Its Bioprocess… August 25, 2022 Biomanufacturing, Bioprocessing
Maintaining CQAs as Manufacturing Processes are Scaled from 2D to 3D Bioreactor Culture February 28, 2022 Biomanufacturing, Quality & Regulatory
Establishing a Working Range for Effective MSC-EV Dose December 16, 2021 Biomanufacturing, Cell Therapy, Exosomes / Extracellular Vesicles
Building Effective Multi-Year Process Development Programs II: Evolution of Technology Platform Decisions… March 30, 2021 BioEconomy, Biomanufacturing, Bioprocessing, Cell Therapy
Building Effective Multi-Year Process Development Programs I: Estimating hMSC Lot Size Ranges for… March 16, 2021 BioEconomy, Biomanufacturing, Bioprocessing, Cell Therapy
Scalable MSC Manufacturing Matters in a Rapid Response to COVID-19 March 13, 2020 Biomanufacturing, Cell Therapy, Corporate, COVID-19
